This study was aimed to evaluate the prognostic value of serum IL-6 (sIL-6) in patients with multiple myeloma (MM). The sIL-6 level in 288 patients with MM was retrospectively analyzed, and the clinical characteristics and prognosis in patients with different IL-6 level were compared. The newly diagnosed patients with MM were divided into two groups: the low sIL-6 group (sIL-6 < 100 pg/ml) and the high sIL-6 group (sIL-6 ≥ 100 pg/ml). The results showed that high sIL-6 level was more common in patients with ECOG score>3, myeloma bone disease (MBD) between grade 2 to 4, and high creatinine level. There was no significant differences in age, abnormal karyotype percentage, chromosome 13q14 abnormality percentage, CD138(+)/CD38(+) cells percentage and the level of calcium, phosphorus, albumin, C-reactive protein, β2-MG, lactate dehydrogenase, hemoglobin, platelet between the two groups at diagnosis, and also no significant difference in response to initial induction chemotherapy among the two groups. The overall survival was significantly different between the low and high IL-6 groups (P = 0.04, 35 m vs 29 m), but no difference in time to progress between the two groups (P = 1.93, 23 m vs 14 m). It is concluded that the sIL-6 level correlates with the clinical characteristics and prognosis. Radioimmunoassay is an appropriate measurement for human IL-6 in serum, and suitable for clinical application.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7534/j.issn.1009-2137.2013.06.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic accuracy of salivary hemoglobin, lactate dehydrogenase and Interleukin-6 to determine chronic periodontitis and tooth loss in type 2 diabetics.
J Oral Biol Craniofac Res
August 2024
Mysore Medical College and Research Institute, Irwin Road, Mysore, 570001, India.
Background: Salivary Hemoglobin (SH) has emerged as the mainstay non-invasive and a practicable screening method for Chronic Periodontitis. Current research aims to comprehensively assess the diagnostic value of Salivary Hb (SH) in comparison with Salivary IL-6 (SIL-6) and levels of Salivary lactate dehydrogenase enzyme (SLDH) amongst Type II Diabetes subjects having Chronic Periodontitis (CP) and associated tooth loss.
Materials And Methods: In this cross-sectional comparative investigation, 240 individuals with at least 15 remaining teeth, ranging in age from 30 to 70, were chosen and Group I controls were defined as follows: healthy (HbA1c levels ≤6.
Codelivery of methotrexate and silibinin by niosome nanoparticles for enhanced chemotherapy of CT26 colon cancer cells.
Biomed Mater
July 2024
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Colon cancer (CC) is one of the most prevalent cancers in the world, and chemotherapy is widely applied to combat it. However, chemotherapy drugs have severe side effects and emergence of multi drug resistance (MDR) is common. This bottleneck can be overcome by niosome nanocarriers that minimize drug dose/toxicity meanwhile allow co-loading of incompatible drugs for combination therapy.
View Article and Find Full Text PDFSalivary Interleukin-6 as a Non-Invasive Biomarker for Chronic Periodontitis and Tooth Loss in Type 2 Diabetes.
Indian J Dent Res
January 2024
Department of Pharmacology, JSS College of Pharmacy (JSS Academy of Higher Education and Research), Rocklands, Ooty, Tamil Nadu, India.
Article Synopsis
- Periodontitis and type 2 diabetes mellitus (T2DM) both elevate levels of Interleukin-6 (IL-6), leading to bone destruction and contributing to dental issues.
- This study involved 240 participants and aimed to explore the role of salivary IL-6 in diagnosing chronic periodontitis (CP) and associated tooth loss in individuals with T2DM.
- Results showed that salivary IL-6 levels were significantly higher in T2DM patients with CP and tooth loss, indicating its potential as a non-invasive biomarker for assessing periodontal disease severity.
Impaired IL-6-induced JAK-STAT signaling in CD4 T cells associates with longer treatment duration in giant cell arteritis.
J Autoimmun
June 2024
Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Pathology and Medical Biology, University of Groningen, Groningen, the Netherlands.
Article Synopsis
- The study explores the role of specific immune pathways (IL-12-IFNγ-Th1 and IL-6-IL-23-Th17) in Giant Cell Arteritis (GCA) and how phosphorylated STAT proteins (pSTAT) in immune cells could help tailor treatments for patients.
- Researchers analyzed immune cells from GCA patients, infection controls, and healthy individuals, noting a decrease in pSTAT3+CD4+T-cells in GCA patients, especially those with high serum IL-6 levels.
- The findings suggest that measuring pSTAT3 levels can predict the duration of glucocorticoid treatment needed for GCA patients, helping to personalize their treatment plans in the future.
Mendelian randomization study on causal association of IL-6 signaling with pulmonary arterial hypertension.
Clin Exp Hypertens
December 2023
Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, China.
Background: A recent Mendelian randomization (MR) did not support an effect of the lead interleukin-6 receptor (IL-6 R) variant on risk of pulmonary arterial hypertension (PAH). Thus, we used two sets of genetic instrumental variants (IVs) and publicly available PAH genome-wide association studies (GWAS) to reassess the genetic causal link between IL-6 signaling and PAH.
Methods: Six independent IL-6 signaling and 34 independent soluble IL-6 receptor (sIL-6 R) genetic IVs from recent MR reports and PAH GWAS including 162,962 European individuals were used to perform this two-sample MR study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!